DT
HealthMore in Health→
MD Anderson team identifies YAP1 as a marker of chemotherapy resistance in relapsed lung cancer
Key Takeaways
- MD Anderson researchers identified YAP1 as a biomarker associated with chemotherapy resistance in relapsed lung cancer.
- The report says some cancer cells express YAP1 only after treatment, helping them survive.
- The finding could support future monitoring and therapy strategies aimed at resistant disease.
DE
DT Editorial Team··via medicalxpress.com
